364 related articles for article (PubMed ID: 7700255)
1. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines.
Wilding TJ; Huettner JE
Mol Pharmacol; 1995 Mar; 47(3):582-7. PubMed ID: 7700255
[TBL] [Abstract][Full Text] [Related]
2. Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors.
Wilding TJ; Huettner JE
Mol Pharmacol; 1996 Mar; 49(3):540-6. PubMed ID: 8643094
[TBL] [Abstract][Full Text] [Related]
3. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
Donevan SD; Yamaguchi S; Rogawski MA
J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
[TBL] [Abstract][Full Text] [Related]
4. AMPA-preferring receptors mediate excitatory synaptic inputs to retinal ganglion cells.
Lukasiewicz PD; Wilson JA; Lawrence JE
J Neurophysiol; 1997 Jan; 77(1):57-64. PubMed ID: 9120596
[TBL] [Abstract][Full Text] [Related]
5. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists.
Yamada KA; Turetsky DM
Br J Pharmacol; 1996 Apr; 117(8):1663-72. PubMed ID: 8732274
[TBL] [Abstract][Full Text] [Related]
6. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles.
Bleakman D; Ballyk BA; Schoepp DD; Palmer AJ; Bath CP; Sharpe EF; Woolley ML; Bufton HR; Kamboj RK; Tarnawa I; Lodge D
Neuropharmacology; 1996; 35(12):1689-702. PubMed ID: 9076748
[TBL] [Abstract][Full Text] [Related]
7. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
Parsons CG; Gruner R; Rozental J
Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977
[TBL] [Abstract][Full Text] [Related]
8. AMPA-preferring receptors mediate excitatory non-NMDA responses of primate retinal ganglion cells.
Jacoby RA; Wu SM
Vis Neurosci; 2001; 18(5):703-10. PubMed ID: 11925006
[TBL] [Abstract][Full Text] [Related]
9. Activation and desensitization of hippocampal kainate receptors.
Wilding TJ; Huettner JE
J Neurosci; 1997 Apr; 17(8):2713-21. PubMed ID: 9092592
[TBL] [Abstract][Full Text] [Related]
10. Differential modulation by cyclothiazide and concanavalin A of desensitization at native alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid- and kainate-preferring glutamate receptors.
Wong LA; Mayer ML
Mol Pharmacol; 1993 Sep; 44(3):504-10. PubMed ID: 7690448
[TBL] [Abstract][Full Text] [Related]
11. Allosteric regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines.
Donevan SD; Rogawski MA
Neuroscience; 1998 Dec; 87(3):615-29. PubMed ID: 9758228
[TBL] [Abstract][Full Text] [Related]
12. Kainate receptor-mediated activation of the AP-1 transcription factor complex in cultured rat cerebellar granule cells.
Kovács AD; Cebers G; Liljequist S
Brain Res Bull; 2000 May; 52(2):127-33. PubMed ID: 10808083
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the dye Evans Blue and GYKI 52466, a 2,3-benzodiazepine, with (S)- alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in cultured rat cortical neurons: electrophysiological evidence for at least two different binding sites for non-competitive antagonists.
Weiser T; Herrmann A; Wienrich M
Neurosci Lett; 1996 Sep; 216(1):29-32. PubMed ID: 8892384
[TBL] [Abstract][Full Text] [Related]
14. Ca2+-permeable non-NMDA glutamate receptors in rat magnocellular basal forebrain neurones.
Waters DJ; Allen TG
J Physiol; 1998 Apr; 508 ( Pt 2)(Pt 2):453-69. PubMed ID: 9508809
[TBL] [Abstract][Full Text] [Related]
15. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors.
Johansen TH; Chaudhary A; Verdoorn TA
Mol Pharmacol; 1995 Nov; 48(5):946-55. PubMed ID: 7476926
[TBL] [Abstract][Full Text] [Related]
16. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death.
Vegh MG; Kovács AD; Kovács G; Szabó G; Tihanyi K; Hársing LG; Lévay G
Neurochem Int; 2007 Feb; 50(3):555-63. PubMed ID: 17147974
[TBL] [Abstract][Full Text] [Related]
17. Protection against non-NMDA receptor-mediated excitotoxicity by GYKI 52466 in mature telencephalic cultures of the rat.
Kovács AD; Egyed A
Neurobiology (Bp); 1996; 4(1-2):59-72. PubMed ID: 9116695
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y release from cultured hippocampal neurons: stimulation by glutamate acting at N-methyl-D-aspartate and AMPA receptors.
Gemignani A; Marchese S; Fontana G; Raiteri M
Neuroscience; 1997 Nov; 81(1):23-31. PubMed ID: 9300398
[TBL] [Abstract][Full Text] [Related]
19. Sustained ethanol inhibition of native AMPA receptors on medial septum/diagonal band (MS/DB) neurons.
Frye GD; Fincher A
Br J Pharmacol; 2000 Jan; 129(1):87-94. PubMed ID: 10694206
[TBL] [Abstract][Full Text] [Related]
20. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.
Donevan SD; Rogawski MA
Neuron; 1993 Jan; 10(1):51-9. PubMed ID: 7678966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
